Hana Biosciences, Inc. Completes Phase 1 Clinical Trial of Menadione, Its Novel First-in-class Compound for Treatment-Limiting Skin Toxicity Associated With EGFR Inhibitors

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the successful completion of its Phase 1 clinical study in healthy volunteers of menadione topical lotion, its novel first-in-class compound in development for the prevention and/or treatment of the acneiform skin rash complication due to anti-cancer therapy with epidermal growth factor receptor (EGFR) inhibitors.

Back to news